The compounds 1 and 6 with high potency and selectivity of inhibition against MAO-A and MAO-B, respectively, may be promising new drug leads for further development as therapeutic treatment of neurological disorders, depression, Alzheimer’s disease, and Parkinson’s disease. This evidence concerns the gene MAOB and Parkinson disease.